Please assess the completion status of the following clinical trial:

Trial Title: Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient eligible for superficial bladder cancer~* Patients must be considered fit for surgical resection with curative intent~* No chemotherapy, surgery (excluding transurethral resection of bladder tumor \[TURBT\], BCG or radiotherapy in the prior 4 weeks \[6 weeks for mitomycin C or interferon\])~* No previous treatment/ingestion with broccoli extracts~* Eastern Oncology Group (ECOG) performance status 0-2~* AST and ALT =\< 2.5 times ULN (upper limit of normal)~* Total bilirubin =\< 2.0 mg/dL~* Creatinine Clearance \>= 30 ml/min~* WBC \> 3000 mm\^3~* Absolute neutrophil count \> 1000/mm\^3~* Platelets \> 100,000/mm\^3~* All patients must sign a study-specific consent form indicating that they are aware of the investigational nature of this study~Exclusion Criteria:~* Have participated in any clinical trial involving conventional or investigational drugs or devices within the previous 4 weeks~* Prior radiation to the pelvis~* Intractable urinary tract infection that has not responded to antibiotic treatment~* Active, uncontrolled bacterial, viral, or fungal infection including HIV~* Have had major surgery within 4 weeks of starting therapy (not including placement of vascular access device or TURBT)~* Poor medical risk in the opinion of the treating oncologist due to non-malignant systemic disease~* Pregnant or lactating patients: patients must be postmenopausal or practicing an accepted form of birth control; for patients where pregnancy is a possibility, a pregnancy test will be required prior to initiation of therapy~* Have a history of myocardial infarction or angina pectoris/angina equivalent in the last 6 months (the patient may be on anti-anginal medications if the symptoms have been entirely controlled for greater than 6 months), or have uncontrolled congestive heart failure~* Have a history of bleeding disorders or thrombosis; patients on therapeutic doses of anticoagulation (including coumadin or heparins) are not permitted on trial (this exclusion criterion does not include those patients receiving low dose or prophylactic dose anticoagulation \[i.e. coumadin 1 mg daily in patients with central intravenous lines\])~* Radiotherapy during the course of the trial~* Inability to tolerate proposed treatment or procedures~* Have additional uncontrolled serious medical conditions or psychiatric illness~* Patients with a history of hepatitis (including but not exclusive to viral hepatitis auto-immune or alcoholic)~* Patients with active thyroid disease (patients with hypothyroidism, adequately replaced on a stable dose of thyroid replacement will be allowed on trial)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity.
- Arm 2 (Type: PLACEBO_COMPARATOR): Patients receive mango juice alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues